Prelude Therapeutics Inc
NASDAQ:PRLD

Watchlist Manager
Prelude Therapeutics Inc Logo
Prelude Therapeutics Inc
NASDAQ:PRLD
Watchlist
Price: 1.46 USD -5.19% Market Closed
Market Cap: 91.8m USD

Prelude Therapeutics Inc
Net Income (Common)

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Prelude Therapeutics Inc
Net Income (Common) Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Net Income (Common) CAGR 3Y CAGR 5Y CAGR 10Y
Prelude Therapeutics Inc
NASDAQ:PRLD
Net Income (Common)
-$127.2m
CAGR 3-Years
-4%
CAGR 5-Years
-36%
CAGR 10-Years
N/A
Abbvie Inc
NYSE:ABBV
Net Income (Common)
$2.3B
CAGR 3-Years
-44%
CAGR 5-Years
-20%
CAGR 10-Years
-2%
Gilead Sciences Inc
NASDAQ:GILD
Net Income (Common)
$8.1B
CAGR 3-Years
34%
CAGR 5-Years
45%
CAGR 10-Years
-7%
Amgen Inc
NASDAQ:AMGN
Net Income (Common)
$7B
CAGR 3-Years
1%
CAGR 5-Years
-1%
CAGR 10-Years
1%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Net Income (Common)
$3.7B
CAGR 3-Years
4%
CAGR 5-Years
6%
CAGR 10-Years
N/A
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Net Income (Common)
$4.6B
CAGR 3-Years
-5%
CAGR 5-Years
8%
CAGR 10-Years
23%
No Stocks Found

Prelude Therapeutics Inc
Glance View

Market Cap
91.8m USD
Industry
Biotechnology

Prelude Therapeutics, Inc. operates as a cancer drug discovery company. The company is headquartered in Wilmington, Delaware and currently employs 116 full-time employees. The company went IPO on 2020-09-25. The firm is focused on discovering and developing small molecule therapies optimized to target the key driver mechanisms in cancers. Its drug discovery engine is designed to identify biological targets and create new chemical entities (NCEs). Its pipeline includes six programs, including methyltransferases, kinases, protein-protein interactions and targeted protein degraders. The firm is developing therapies in both solid tumors and hematological malignancies, such as adenoid cystic carcinoma (ACC), homologous recombination deficient positive (HRD+), cancers, myelofibrosis (MF) and glioblastoma multiforme (GBM), amongst others. The Company’s product candidates include PRT543, PRT811, PRT1419, PRT2527, PRT-SCA2 and PRT-K4.

PRLD Intrinsic Value
1.7 USD
Undervaluation 14%
Intrinsic Value
Price

See Also

What is Prelude Therapeutics Inc's Net Income (Common)?
Net Income (Common)
-127.2m USD

Based on the financial report for Dec 31, 2024, Prelude Therapeutics Inc's Net Income (Common) amounts to -127.2m USD.

What is Prelude Therapeutics Inc's Net Income (Common) growth rate?
Net Income (Common) CAGR 5Y
-36%

Over the last year, the Net Income (Common) growth was -4%. The average annual Net Income (Common) growth rates for Prelude Therapeutics Inc have been -4% over the past three years , -36% over the past five years .

Back to Top